EpilepsyGTx raised $33 million in Series A funding. Investors include XGEN Venture, the British Business Bank, and a global biopharma company. The round follows $10 million in pre-seed and seed from UCL Technology Fund and others.

The money supports first-in-human Phase I/IIa trials for EPY201. This AAV gene therapy treats focal refractory epilepsy. It reduces hyperexcitability at the seizure focus with local delivery. Patients could gain seizure freedom from one treatment, skipping surgery or long-term drugs.

EpilepsyGTx plans a pipeline of gene therapies for refractory epilepsy and hyperexcitability disorders. EPY201 uses AAV9 capsid, CAMK2A promoter, and engineered Kv1.1 channel via intraparenchymal administration. Focal epilepsy starts in one brain area and resists two or more antiseizure meds.

Nicolas Koebel, CEO, said refractory epilepsy hits millions with dangerous seizures. EPY201 could stop them with one minimally invasive dose. It shifts how this condition gets treated after decades.

EpilepsyGTx develops gene therapies for refractory epilepsy. Based in London, UK, it targets focal cases where seizures resist standard drugs. The lead program EPY201 and pipeline aim at neuronal hyperexcitability disorders for better patient outcomes.

OpenAI has acquired US health-tech startup Torch for more than USD 100 million. The acquisition brings Torch into OpenAI’s growing healthcare efforts, including its recently launched ChatGPT Health feature.

Torch has been building a product that helps users bring scattered medical records into one place and use AI to better understand them. OpenAI said Torch’s work fits closely with ChatGPT Health, which lets users upload health data and talk to the chatbot about test results, appointments, diet, and workouts.

OpenAI said privacy will remain a priority. The company has committed that health data and conversations inside ChatGPT Health will stay private and will not be used to train its core AI models. Torch’s leadership team and employees are expected to join OpenAI as part of the deal.

Torch was founded in January 2025 and focuses on helping people make sense of their medical information using AI. The company serves individuals who want a clearer view of their health data and how it connects across hospitals, labs, and devices. It operates in the United States.

Dr. Paws closed INR 29.3 crore in a pre-Series A round. Chiratae Ventures led the funding. Existing backer Sauce took part again. There was also venture debt from Trifecta Capital and Stride Ventures.

The money will help add nine new clinics in Bengaluru by 2026. The company also plans to open in Hyderabad and Pune. It will start at-home vet services and its own products like treats, supplements, and pet food. The team will put some cash into tech for better workflows, customer tools, and training. They are also adding people to the leadership team for city and central roles.

Dr. Paws runs veterinary clinics in Bengaluru. The clinics handle consultations, surgeries, diagnostics, and preventive care for pets. The company now has three 24x7 locations open and two more coming soon.

Earthful secured INR 26 crore in a pre-Series A round. The deal was led by Fireside Ventures and V3 Ventures. Atrium Angels also participated.

The funds will help grow the women-focused product line, including menopausal health items. They will also go toward building the team and pushing sales across D2C channels, Amazon, Flipkart, and Blinkit.

Earthful sells clean-label, plant-based nutrition products. It offers multivitamins, proteins, and targeted options for sleep, skin, and hair. The company is based in Hyderabad and runs as a direct-to-consumer brand in India.

PsiThera raised $47.5 million in Series A financing. Samsara Biocapital and Lightstone Ventures led the equity round. Other investors include Roivant, YK Bioventures, Eurofarma Ventures, and more. The company came from a Roivant spinout and now runs independently.

Eric Shaff started as CEO. He brings experience from Seres Therapeutics. The leadership also has Woody Sherman as Founder and Chief Innovation Officer, and Camil Sayegh as Chief Scientific Officer.

The funding advances a pipeline of oral drugs for immune and inflammatory diseases. It starts with TNF superfamily programs. The company uses its QUAISAR platform with molecular dynamics and AI to model proteins and drugs.

Investors like the setup. Christina Isacson from Lightstone Ventures, now board chair, said it mixes computation and science well for tough targets. Eric Shaff said the platform sped their lead program from hit to optimization in four months. Woody Sherman said it beats limits of old methods on moving molecules.

PsiThera makes oral drugs for immune and inflammatory diseases. It uses biophysics, AI modeling, and biology to hit targets once limited to injectables. The pipeline targets TNF superfamily members for patients with those conditions.

Amplifold raised EUR 5 million in an oversubscribed Seed round. The round was co-led by Matterwave Ventures and XISTA Science Ventures. Bayern Kapital, b2venture, and Becker Ventures (part of Labor Becker Group) also invested.

The funds will help industrialise the DNA-origami signal amplification platform for lateral flow assays. They will support product development and regulatory work to get the first in vitro diagnostic product approved under IVDR in Europe.

Dr Enzo Kopperger, co-founder and managing director, said the tech can give about 100 times better sensitivity without much extra cost. It fits into existing manufacturing lines so partners can improve their tests quickly without starting over.

Dr Maximilian Urban, co-founder and managing director, said lateral flow tests made diagnostics more accessible but were not as sensitive as lab equipment. The DNA-origami boost lets cheap rapid tests get close to that lab-level accuracy while keeping the same simple format.

Amplifold builds rapid diagnostic tests using DNA-origami nanotechnology. The platform boosts sensitivity in standard lateral flow assays for better detection. The company is a spin-off from Ludwig-Maximilians-Universität München and operates in Germany.

Radial raised $50 million in venture funding. General Catalyst led the Series A round. Other investors include Solari Capital, JSL Health Capital, Founder Collective, BoxGroup, Scrub Capital, and Diede van Lamoen.

The backers support Radial’s push to make advanced mental health treatments available. These include neuromodulation like TMS and fast-acting drugs like Spravato. The company aims to fix gaps in the healthcare system for these therapies.

The funding will help expand a national network of clinics. It accepts most major insurance like Medicare, Tricare, VA-CCN, Aetna, Cigna, United, and Blues plans. Radial also builds software for clinical workflows, insurance, and decisions. Plans call for more clinics and tech partnerships in 2026.

John Capecelatro, CEO and co-founder, said new treatments work in days or weeks, not years. He noted remission rates of 50-60% or up to 78% in studies. Radial provides the tools and paths to get these to patients faster.

Reva Nohria from General Catalyst said psychiatry is changing but infrastructure lags. Radial knows the clinical side and operations to deliver care at scale. Owen Muir, Chief Medical Officer, said research shows these treatments work, and Radial brings them to everyday practice.

Radial develops tools for advanced mental health care. It includes clinics, insurance help, and decision support for treatments like TMS and Spravato. The company operates in six states now and plans national growth for patients, providers, and payers.